Dominik Maurer joined Immatics Biotechnologies GmbH in 2008 the Immunology department.
For 10+ years Dominik has been active in the field of cancer immunotherapy and a leader in human T-cell biology. He invented and developed with his team the Immatics’s T-Cell Receptor (TCR) technology platform XCEPTOR™ which is enabling the fast and efficient discovery, engineering and qualification of a large number of high-affinity and high-specificity TCRs that can be used for Adoptive Cell Therapies i.e. ACTengine® and ACTallo® and TCER™ - Bispecifics.
Dominik leads a global-acting Immunology department consisting of four divisions responsible for the TCR discovery platform XCEPTOR™, TCER™ - Bispecifics preclinical development, cellular & molecular Immunomonitoring, and Product Science of adoptive cell therapies.
Dominik is an inventor of 10+ patents and patent applications and has co-authored 10+ publications in peer-reviewed journals including Nature, Nature Medicine, Science Immunology, Immunity, Lancet Oncology.
Dominik Maurer gained his Ph.D. in Immunology from the University of Tuebingen, Germany.